EMEA-000885-PIP01-10 - paediatric investigation plan

Telmisartan

hydrochlorothiazide

Key facts

• Invented name:
  • MicardisPlus
  • MicardisPlus
• Active Substance:
  • Telmisartan
  • hydrochlorothiazide
• Therapeutic area:
  Cardiovascular diseases
• Decision number:
  P/159/2010
• PIP number:
  EMEA-000885-PIP01-10
• Pharmaceutical form(s):
  Tablet
• Condition(s) / indication(s):
  Treatment of hypertension
• Route(s) of administration:
  Oral use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  27/08/2010

Decision

P/159/2010: EMA decision of 27 August 2010 on the agreement of a paediatric investigation plan and on the granting of a product specific waiver for telmisartan / hydrochlorothiazide (MicardisPlus) (EMEA-000885-PIP01-10)

AdoptedReference Number: EMA/477373/2010